Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field.  In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.

Chapters

• 1:14 What have you have been working on lately?
• 1:37 What is the latest R&D progress in the in vivo CAR-T cell therapy field?
• 3:10 Why is lipid nanoparticle technology ideal for in vivo CAR-T cell engineering?
• 5:37 Advantages of lipid nanoparticles over other gene delivery platforms
• 10:22 Exploring the cell targeting, systemic delivery potential, and broad applicability of LNPs
• 12:45 What LNP learnings from the mRNA field can be leveraged for CAR-T cell engineering?
• 15:25 What is the most surprising thing you have learned in your preclinical work to date?
• 15:50 What are you most excited about in terms of Capstan's future work?
• 17:03 What is Capstan's biggest challenge today and how are you addressing it?
• 17:59 What will be Capstan's biggest challenge in five years’ time? How to prepare for it?